The US cancer vaccine market is expected to display higher growth rate over the next seven years. The US cancer vaccine market is subject to witness a substantial growth due to the rising occurrence of cancer and rising awareness among general population. Increasing healthcare expenditure and recent improvements in the healthcare infrastructure, particularly in the North America region are expected to fuel market demand for cancer vaccine in the upcoming years. The US cancer vaccine market is predicted to generate massive revenue over next seven years, providing numerous opportunities for market players to invest for research and development in the US cancer vaccine market. Soaring demand for advanced analytical techniques for treatment of cancer is predicted to favor market growth in the upcoming years. In addition, surging need for fewer intrusive surgeries and introduction of disposable instruments is projected to foster the growth of US cancer vaccine market over the forecast period. The recent technological advancement coupled with development of the novel products & techniques such as genetic therapy are expected to provide platform for the sustained growth of US cancer vaccine market in the upcoming years. Rising influence of commercialization and digitalization in healthcare sector are driving demand of the cancer vaccine, in the recent years. Furthermore, recent technological advancement and increasing adoption of digital services in healthcare sector is leading increasing commercialization of next generation diagnostic is expected to fuel market demand for cancer vaccine over the forecast period. Treatment associated with diseases such as multiple sclerosis, cancer, and other types of infectious disorders are highly expensive majorly due to higher cost of pharmaceuticals. Numerous regional governments are making sincere efforts for development of cost-effective vaccine. Furthermore, rising in the healthcare expenditure by developed countries such as U.S. are aggravating demand for the cost-effective vaccines. Subsequently, factors such as price regulations and increasing of healthcare budget in U.S. are raising demand for cost-effectiveness in healthcare sector. The US cancer vaccine market is broadly categorized into major segments based on the product type such as therapeutic and prophylactic vaccine. The therapeutic is considered as one of the fastest growing segment in the US cancer vaccine market with substantial revenue generation in the last few years. Growing popularity of cancer vaccine in the therapeutic segment is attributed to the increasing number of cancer patients and long known viability of these products. The prophylactic vaccine segment has also witnessed substantial growth owing to the higher approval rate and increasing market penetration. U.S. has shown major growth in recent years owing to the rise in the implementation of latest technologies in medicine & healthcare sector, increase in the number of research & development activities in the region and existence of well-established medical infrastructure. The key players in the US cancer vaccine market are Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals LLC, Bristol-Myers Squibb Co., and Merck & Co., Ltd. Cancer involves abnormal and uncontrolled cell growth which may spread to other parts of the body as well. According to GLOBOCAN, in 2015, approximately 15.2 Million incidences of cancer were registered all across the globe. Out of total, US accounted for approximately 1.7 Million incidences of this deadly disease. Cancer is also one of the leading causes of mortality. Traditional treatment options, such as surgery, chemotherapy and radiotherapy, have several drawbacks such as hair loss, abnormal blood cell count and nausea. One of the major drawbacks of traditional cancer treatment therapies is the risk of remission in patient. Owing to all these shortcomings, researchers are developing novel treatment options, such as cancer vaccines, for this disease. Cancer vaccines have always been considered as high potential method for preventing and treating cancer even though they have not been able to achieve their expected sales. However, the market for these vaccines is expected to witness decent growth in the coming years due to the launch of new cancer vaccines and increasing awareness among people about this treatment option. According to the RNCOS report entitled “Promising Outlook - US Cancer Vaccine Market”, the US is largest market for cancer vaccines amongst all the geographic regions worldwide. The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing cancer incidences in the country, rising awareness, and strong pipeline, for the US Cancer Vaccines Market. Furthermore, the report also gives information related to the commercially available cancer vaccines. It also covers the restraints hampering the growth of the market, and future opportunities. On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounted for the largest share in 2017. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline. Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent. The prominent players in US Cancer Vaccines Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the US Cancer Vaccines Market.
Table Of Content 1. Analyst View 2. Research Methodology 3. Cancer Statistics by Demographics 3.1 Prevalence, Incidences and Mortality 3.2 Leading States by Incidences 3.3 Leading Cancers by Incidences 3.3.1 Male Cancer Incidences 3.3.2 Female Cancer Incidences 3.3.3 Children Cancer Incidences 4. Market Dynamics 4.1 Drivers 4.1.1 Rising Cancer Incidences 4.1.2 Ability to Reduce Healthcare Expenditure 4.1.3 Rising Awareness 4.1.4 Patient Assistance Programs 4.1.5 Government Initiatives 4.1.6 Strong Pipeline 4.1.7 Technological Advancements 4.2 Restraints 4.2.1 High Cost of Cancer Vaccines 4.2.2 Side-Effects of Cancer Vaccines 4.2.3 Vaccine Supply Shortages 4.2.4 Insurance Issues Related to Cancer Vaccination 4.3 Opportunities 4.3.1 Therapeutic Cancer Vaccines 4.3.2 Adjuvant Cancer Vaccines 5. Cancer Vaccines Market Outlook 5.1 Key Product Analysis 5.1.1 Provenge 188.8.131.52 Market Analysis 5.1.2 T-Vec/Imlygic 184.108.40.206 Market Analysis 5.1.3 HPV Vaccine 220.127.116.11 Gardasil 18.104.22.168.1 Market Analysis 22.214.171.124 Cervarix 126.96.36.199.1 Market Analysis 5.1.4 HBV Vaccines 188.8.131.52 Engerix-B & Twinrix 184.108.40.206.1 Market Analysis 220.127.116.11 Recombivax HB 18.104.22.168.1 Market Analysis 22.214.171.124 Pediarix/ Infanrix 126.96.36.199.1 Market Analysis 6. Cancer Vaccines Market by Cancer Type 7. Cancer Vaccine Market by Application 8. Potential Cancer Vaccine Candidates: An Opportunity Assessment 8.1 Prophylactic Vaccine 8.2 Therapeutic Vaccine 8.2.1 Prostate Cancer 8.2.2 Breast Cancer 8.2.3 Lung Cancer 8.2.4 Colorectal Cancer 9. US Patent Analysis 9.1 Patents by Year 9.2 Patents by Category 9.2.1 Utility Patents 9.2.2 Design Patents 9.2.3 Plant Patents 9.3 Patents by Company 9.4 Patents by Assignee Type 9.4.1 By Assignee Name 9.4.2 By Assignee State 10. Regulatory Environment 10.1 Vaccine Approval Process 10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines 10.2.1 Considerations for both Early and Late Phase Clinical Trials 10.2.1.1 Patient Population 10.2.1.2 Monitoring the Immune Response 10.2.1.3 Biomarkers as Evidence of Efficacy 10.2.1.4 Adjuvants Used to Stimulate Immune Response 10.2.1.5 Multi-antigen Vaccines 10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines 10.2.1.7 Concomitant and Subsequent Therapies 10.2.2 Considerations for Early Phase Clinical Trials 10.2.2.1 Starting Dose and Dosing Schedule 10.2.2.2 Booster and Maintenance Therapy 10.2.2.3 Dose Escalation 10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development 10.2.3 Considerations for Late Phase Clinical Trials 10.2.3.1 Safety Profile from Early Phase Clinical Trials 10.2.3.2 Endpoints 10.2.3.3 Statistical Issues 10.2.3.4 Control Issues 10.2.3.5 Delayed Vaccine Effect 10.2.3.6 Autologous Vaccine Trials 10.2.3.7 Accelerated Approval Regulations 11. Competitive Landscape 12. Company Profiles 12.1 Merck & Co., Inc. 12.2 GlaxoSmithKline plc. 12.3 Dendreon Pharmaceuticals LLC 12.4 Amgen Inc.
List of Tables: Table 3-1: Top 10 Cancer Incidences in Males (2018) Table 3-2: Top 10 Cancer Incidences in Females (2018) Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2018) Table 4-1: Cancer Incidences (Million), 2015, 2020 & 2025 Table 8-1: Cancers with High Linkage to Virus and Bacteria Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials Table 12-1: Merck & Co., Inc. - Key Financials (Million US$), 2015-2017 Table 12-2: Merck & Co., Inc. - Product Portfolio Table 12-3: Merck & Co., Inc. - Cancer Vaccines in Pipeline Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2015-2017 Table 12-5: GlaxoSmithKline - Product Portfolio Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline Table 12-7: Dendreon Pharmaceuticals LLC - Product Portfolio Table 12-8: Amgen Inc. - Key Financials (Million US$), 2015-2017 Table 12-9: Amgen Inc. - Product Portfolio List of Figures: Figure 3-1: Cancer Incidences (Million), 2015 & 2025 Figure 3-2: Cancer Mortality (Million), 2015 & 2025 Figure 3-3: Incidences by Cancer Type (%), 2018 Figure 3-4: States with Highest Cancer Incidences, 2018 Figure 5-1: Global - Cancer Vaccine Market (Million US$), 2016-2023 Figure 5-2: US - Cancer Vaccine Market (Million US$), 2016-2023 Figure 5-3: Share of US in Global Cancer Vaccine Market (%), 2017 Figure 5-4: US - Cancer Vaccine Market by Product Type (%), 2017 Figure 5-5: US - Provenge Market (Million US$), 2013-2017 Figure 5-6: Share of US in Global Imlygic Sales (%), 2017 Figure 5-7: Global - Gardasil Market (Million US$), 2013-2017 Figure 5-8: US - Gardasil Market (Million US$), 2013-2017 Figure 5-9: Share of US in Global Gardasil Sales (%), 2017 Figure 5-10: Global - Cervarix Market (Million US$), 2013-2017 Figure 5-11: US - Cervarix Market (Million US$), 2013-2017 Figure 5-12: Share of US in Global Cervarix Sales (%), 2017 Figure 5-13: Global - Engerix-B & Twinrix Market (Million US$), 2013-2017 Figure 5-14: US - Engerix-B & Twinrix Market (Million US$), 2013-2017 Figure 5-15: Share of US in Global Engerix-B & Twinrix Sales (%), 2017 Figure 5-16: Global - Recombivax HB Market (Million US$), 2013-2017 Figure 5-17: US - Recombivax HB Market (Million US$), 2013-2017 Figure 5-18: Share of US in Global Recombivax HB Sales (%), 2017 Figure 5-19: Global - Pediarix/Infanrix Market (Million US$), 2013-2017 Figure 5-20: US - Pediarix/ Infanrix Market (Million US$), 2013-2017 Figure 5-21: Share of US in Global Pediarix/Infanrix Sales (%), 2017 Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2017 Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2016-2023 Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2016-2023 Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2016-2023 Figure 7-1: US - Cancer Vaccine Market by Application (%), 2017 Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2016-2023 Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2016-2023 Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017 Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2017 Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2017 Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2017 Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2017 Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2017 Figure 12-1: Merck & Co., Inc. - Breakup of Sales by Business Segment (%), 2017 Figure 12-2: Merck & Co., Inc. - Breakup of Sales by Geography (%), 2017 Figure 12-3: GlaxoSmithKline - Breakup of Group Turnover by Business Segment (%), 2017 Figure 12-4: GlaxoSmithKline - Breakup of Group Turnover by Geography (%), 2017 Figure 12-5: Amgen Inc. - Breakup of Revenue by Geography (%), 2017
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.